ClinicalTrials.gg

Program

Methylprednisolone

Also written as “methylprednisolone”, “Vasopressin; Methylprednisolone; Hydrocortisone” and “Methylprednisolone/prednisolone”.

Its studies are mostly in Multiple Sclerosis, Relapsing-Remitting · Multiple Myeloma · Diabetes Insipidus · Myopathies, Structural, Congenital · Gaucher Disease, led by 9 companies.

Furthest: phase 4, since May 27, 200516 company-led studies, 4 open or runningNext primary completion: Feb 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biogen40 open or runningphase 4since May 27, 2005May 27, 2005none ahead
Pfizer40 open or runningphase 1since Dec 13, 2010Dec 13, 2010none ahead
Oncotherapeutics22 open or runningphase 1since Nov 7, 2023Nov 7, 2023Apr 1, 2027phase 1 · NCT06225310
amsterdam-molecular-therapeutics10 open or runningphase 3since Apr 30, 2009Apr 30, 2009none ahead
Astellas Pharma11 open or runningphase 2since Jun 30, 2025Jun 30, 2025Oct 31, 2027phase 2 · NCT07052929
Bristol-Myers Squibb10 open or runningphase 2since May 4, 2016May 4, 2016none ahead
Chong Kun Dang Pharmaceutical10 open or runningphase 4since Jan 3, 2019Jan 3, 2019none ahead
Eli Lilly11 open or runningphase 2since May 11, 2020May 11, 2020Feb 2027phase 2 · NCT04411654
Sun Pharmaceutical Industries10 open or runningphase 2since Oct 31, 2016Oct 31, 2016none ahead

Also a collaborator on its studies: Incyte, elan-pharmaceuticals and the-clinical-trial-company.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 27, 2005First study: phase 4 study in Multiple Sclerosis, Relapsing-RemittingNew to BiogenBiogen · NCT00112034 · 350 enrolled · United States
  2. Jun 25, 20072 phase 4 studies in Multiple Sclerosis, Relapsing-RemittingBiogen · NCT00493116, NCT00492466
  3. Apr 30, 2009amsterdam-molecular-therapeutics's first study: phase 3 study in Hyperlipoproteinemia Type INew to amsterdam-molecular-therapeuticsamsterdam-molecular-therapeutics · NCT00891306 · 5 enrolled · Canada
  4. Feb 17, 2010Phase 2 study in Multiple Sclerosis, Relapsing-RemittingBiogen · NCT01071083 · 175 enrolled · United States, Germany, Spain
  5. Dec 13, 2010Pfizer's first study: phase 1 study in Biological AvailabilityNew to PfizerPfizer · NCT01267201 · 24 enrolled · Singapore
  6. Jul 25, 20113 phase 1 studiesPfizer · NCT01405170, NCT01405157, NCT01405131
  7. May 4, 2016Bristol-Myers Squibb's first study: phase 2 study in Carcinoma, Renal CellNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT02763761 · United States
  8. Oct 31, 2016Sun Pharmaceutical Industries's first study: phase 2 study in Prostatic NeoplasmsNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT02962284 · 20 enrolled
  9. Jan 3, 2019Chong Kun Dang Pharmaceutical's first study: phase 4 study in Kidney TransplantNew to Chong Kun Dang PharmaceuticalChong Kun Dang Pharmaceutical · NCT03794492 · 169 enrolled · Korea, Republic of
  10. May 11, 2020Eli Lilly's first study: phase 2 study in Gaucher DiseaseNew to Eli LillyEli Lilly · NCT04411654 · 7 enrolled · United States, United Kingdom
  11. Nov 7, 2023Oncotherapeutics's first study: phase 1 study in Multiple MyelomaNew to OncotherapeuticsOncotherapeutics · NCT06225310 · 30 planned · United States
  12. Jan 8, 2024Early phase 1 study in Multiple MyelomaOncotherapeutics · NCT06209606 · 30 planned · United States
  13. Jun 30, 2025Astellas Pharma's first study: phase 2 study in Myopathies, Structural, CongenitalNew to Astellas PharmaAstellas Pharma · NCT07052929 · 9 planned · United States, Canada

Ahead

  1. Feb 2027Primary completion: phase 2 study in Gaucher DiseaseEli Lilly · NCT04411654
  2. Apr 1, 2027Primary completion: phase 1 study in Multiple MyelomaOncotherapeutics · NCT06225310
  3. Oct 31, 2027Primary completion: phase 2 study in Myopathies, Structural, CongenitalAstellas Pharma · NCT07052929

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor agonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
DexamethasoneruleAbbViephase 4174
BudesonideruleAstraZenecaphase 4167
fluticasone furoateruleGlaxoSmithKlinephase 497
PrednisoneruleJohnson & Johnsonphase 465
BeclomethasoneruleChiesi Farmaceuticiphase 446
PrednisoloneruleSanofiphase 434
betamethasone dipropionateruleLEO Pharmaphase 427
dexamethasone phosphateruleeyegate-pharmaceuticals-incphase 421
vamorolonerulereveragen-biopharma-incphase 411
BetamethasoneruleLEO Pharmaphase 49
Triamcinoloneruleresearch-insight-llcphase 45
relacorilantruleCorcept Therapeuticsphase 322

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07052929Myopathies, Structural, Congenital · United States, Canada2RecruitingAstellas PharmaOct 31, 20279
NCT06209606Multiple Myeloma · United StatesEarly 1RecruitingOncotherapeuticsMay 202630
NCT06225310Multiple Myeloma · United States1RecruitingOncotherapeuticsApr 1, 202730
NCT04411654Gaucher Disease · United States, United Kingdom2Active, not recruitingEli LillyFeb 20277
NCT03794492Kidney Transplant · Korea, Republic of4CompletedChong Kun Dang PharmaceuticalJul 22, 2022169
NCT02962284Prostatic Neoplasms2CompletedSun Pharmaceutical IndustriesMar 201820
NCT02763761Carcinoma, Renal Cell · United States2WithdrawnBristol-Myers SquibbMar 31, 20170
NCT01405170Lecithin Cholesterol Acyltransferase Deficiency1WithdrawnPfizerOct 28, 20110
NCT01405157Fasting1WithdrawnPfizerFeb 20, 20120
NCT01405131Therapeutic Equivalency1WithdrawnPfizerFeb 20, 20120
NCT01267201Biological Availability · Singapore1CompletedPfizerDec 201024
NCT01071083Multiple Sclerosis, Relapsing-Remitting · United States, Germany, Spain2CompletedBiogenNov 2011175
NCT00891306Hyperlipoproteinemia Type I · Canada3Completedamsterdam-molecular-therapeuticsAug 20105
NCT00493116Multiple Sclerosis, Relapsing-Remitting · Australia, New Zealand4CompletedBiogenDec 200920
NCT00492466Multiple Sclerosis, Relapsing-Remitting · Finland4CompletedBiogenAug 200614
NCT00112034Multiple Sclerosis, Relapsing-Remitting · United States4CompletedBiogenJun 2006350

How it is read

Names in the registry

  • “methylprednisolone”, 16 entries
  • “Methylprednisolone”, 7 entries
  • “Vasopressin; Methylprednisolone; Hydrocortisone”, 1 entry
  • “Methylprednisolone/prednisolone”, 1 entry
  • “abiraterone acetate with Methylprednisolone”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.